Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

Naga P. Chalasani, Arun J. Sanyal, Kris V. Kowdley, Patricia R. Robuck, Jay Hoofnagle, David E. Kleiner, Aynur Ünalp, James A Tonascia

Research output: Contribution to journalArticle

Abstract

Background: Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes. NASH is a progressive disorder that can lead to cirrhosis and liver failure. Insulin resistance and oxidative stress are thought to play important roles in its pathogenesis. There is no definitive treatment for NASH. Objectives: PIVENS is conducted to test the hypotheses that treatment with pioglitazone, a thiazolidinedione insulin sensitizer, or vitamin E, a naturally available antioxidant, will lead to improvement in hepatic histology in non-diabetic adults with biopsy proven NASH. Design: PIVENS is a randomized, multicenter, double-masked, placebo-controlled trial to evaluate whether 96 weeks of treatment with pioglitazone or vitamin E improves hepatic histology in non-diabetic adults with NASH compared to treatment with placebo. Before and post-treatment liver biopsies are read centrally in a masked fashion for an assessment of steatohepatitis and a NAFLD Activity Score (NAS) consisting of steatosis, lobular inflammation, and hepatocyte ballooning. The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. Methods: PIVENS enrollment started in January 2005 and ended in January 2007 with 247 patients randomized to receive either pioglitazone (30 mg q.d.), vitamin E (800 IU q.d.), or placebo for 96 weeks. Participants will be followed for an additional 24 weeks after stopping the treatment. The study protocol incorporates the use of several validated questionnaires and specimen banking. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management. (ClinicalTrials.gov number, NCT00063622.).

Original languageEnglish (US)
Pages (from-to)88-96
Number of pages9
JournalContemporary Clinical Trials
Volume30
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

pioglitazone
Fatty Liver
Vitamin E
Placebos
Therapeutics
Hepatocytes
Liver
Histology
Fibrosis
Clinical Trials Data Monitoring Committees
Biopsy
Research Ethics Committees
Liver Failure
Patient Safety
Insulin Resistance
Liver Diseases
Oxidative Stress

Keywords

  • Non-alcoholic steatohepatitis
  • Peroxisome proliferator-activated receptor-gamma (PPAR-γ)
  • Pioglitazone
  • Randomized controlled trial
  • RRR-α-tocopherol
  • Thiazolidinedione
  • Vitamin E

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis : PIVENS trial design. / Chalasani, Naga P.; Sanyal, Arun J.; Kowdley, Kris V.; Robuck, Patricia R.; Hoofnagle, Jay; Kleiner, David E.; Ünalp, Aynur; Tonascia, James A.

In: Contemporary Clinical Trials, Vol. 30, No. 1, 01.2009, p. 88-96.

Research output: Contribution to journalArticle

Chalasani, Naga P. ; Sanyal, Arun J. ; Kowdley, Kris V. ; Robuck, Patricia R. ; Hoofnagle, Jay ; Kleiner, David E. ; Ünalp, Aynur ; Tonascia, James A. / Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis : PIVENS trial design. In: Contemporary Clinical Trials. 2009 ; Vol. 30, No. 1. pp. 88-96.
@article{c29465e1253d4fc0a8b83379d4647369,
title = "Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design",
abstract = "Background: Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes. NASH is a progressive disorder that can lead to cirrhosis and liver failure. Insulin resistance and oxidative stress are thought to play important roles in its pathogenesis. There is no definitive treatment for NASH. Objectives: PIVENS is conducted to test the hypotheses that treatment with pioglitazone, a thiazolidinedione insulin sensitizer, or vitamin E, a naturally available antioxidant, will lead to improvement in hepatic histology in non-diabetic adults with biopsy proven NASH. Design: PIVENS is a randomized, multicenter, double-masked, placebo-controlled trial to evaluate whether 96 weeks of treatment with pioglitazone or vitamin E improves hepatic histology in non-diabetic adults with NASH compared to treatment with placebo. Before and post-treatment liver biopsies are read centrally in a masked fashion for an assessment of steatohepatitis and a NAFLD Activity Score (NAS) consisting of steatosis, lobular inflammation, and hepatocyte ballooning. The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. Methods: PIVENS enrollment started in January 2005 and ended in January 2007 with 247 patients randomized to receive either pioglitazone (30 mg q.d.), vitamin E (800 IU q.d.), or placebo for 96 weeks. Participants will be followed for an additional 24 weeks after stopping the treatment. The study protocol incorporates the use of several validated questionnaires and specimen banking. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management. (ClinicalTrials.gov number, NCT00063622.).",
keywords = "Non-alcoholic steatohepatitis, Peroxisome proliferator-activated receptor-gamma (PPAR-γ), Pioglitazone, Randomized controlled trial, RRR-α-tocopherol, Thiazolidinedione, Vitamin E",
author = "Chalasani, {Naga P.} and Sanyal, {Arun J.} and Kowdley, {Kris V.} and Robuck, {Patricia R.} and Jay Hoofnagle and Kleiner, {David E.} and Aynur {\"U}nalp and Tonascia, {James A}",
year = "2009",
month = "1",
doi = "10.1016/j.cct.2008.09.003",
language = "English (US)",
volume = "30",
pages = "88--96",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis

T2 - PIVENS trial design

AU - Chalasani, Naga P.

AU - Sanyal, Arun J.

AU - Kowdley, Kris V.

AU - Robuck, Patricia R.

AU - Hoofnagle, Jay

AU - Kleiner, David E.

AU - Ünalp, Aynur

AU - Tonascia, James A

PY - 2009/1

Y1 - 2009/1

N2 - Background: Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes. NASH is a progressive disorder that can lead to cirrhosis and liver failure. Insulin resistance and oxidative stress are thought to play important roles in its pathogenesis. There is no definitive treatment for NASH. Objectives: PIVENS is conducted to test the hypotheses that treatment with pioglitazone, a thiazolidinedione insulin sensitizer, or vitamin E, a naturally available antioxidant, will lead to improvement in hepatic histology in non-diabetic adults with biopsy proven NASH. Design: PIVENS is a randomized, multicenter, double-masked, placebo-controlled trial to evaluate whether 96 weeks of treatment with pioglitazone or vitamin E improves hepatic histology in non-diabetic adults with NASH compared to treatment with placebo. Before and post-treatment liver biopsies are read centrally in a masked fashion for an assessment of steatohepatitis and a NAFLD Activity Score (NAS) consisting of steatosis, lobular inflammation, and hepatocyte ballooning. The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. Methods: PIVENS enrollment started in January 2005 and ended in January 2007 with 247 patients randomized to receive either pioglitazone (30 mg q.d.), vitamin E (800 IU q.d.), or placebo for 96 weeks. Participants will be followed for an additional 24 weeks after stopping the treatment. The study protocol incorporates the use of several validated questionnaires and specimen banking. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management. (ClinicalTrials.gov number, NCT00063622.).

AB - Background: Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes. NASH is a progressive disorder that can lead to cirrhosis and liver failure. Insulin resistance and oxidative stress are thought to play important roles in its pathogenesis. There is no definitive treatment for NASH. Objectives: PIVENS is conducted to test the hypotheses that treatment with pioglitazone, a thiazolidinedione insulin sensitizer, or vitamin E, a naturally available antioxidant, will lead to improvement in hepatic histology in non-diabetic adults with biopsy proven NASH. Design: PIVENS is a randomized, multicenter, double-masked, placebo-controlled trial to evaluate whether 96 weeks of treatment with pioglitazone or vitamin E improves hepatic histology in non-diabetic adults with NASH compared to treatment with placebo. Before and post-treatment liver biopsies are read centrally in a masked fashion for an assessment of steatohepatitis and a NAFLD Activity Score (NAS) consisting of steatosis, lobular inflammation, and hepatocyte ballooning. The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. Methods: PIVENS enrollment started in January 2005 and ended in January 2007 with 247 patients randomized to receive either pioglitazone (30 mg q.d.), vitamin E (800 IU q.d.), or placebo for 96 weeks. Participants will be followed for an additional 24 weeks after stopping the treatment. The study protocol incorporates the use of several validated questionnaires and specimen banking. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management. (ClinicalTrials.gov number, NCT00063622.).

KW - Non-alcoholic steatohepatitis

KW - Peroxisome proliferator-activated receptor-gamma (PPAR-γ)

KW - Pioglitazone

KW - Randomized controlled trial

KW - RRR-α-tocopherol

KW - Thiazolidinedione

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=57549107354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549107354&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2008.09.003

DO - 10.1016/j.cct.2008.09.003

M3 - Article

C2 - 18804555

AN - SCOPUS:57549107354

VL - 30

SP - 88

EP - 96

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 1

ER -